We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

RSV and Aging: Understanding Increased Vulnerability

Source: Pharmacy Times articles New research reveals how aging weakens immune responses to RSV in older adults, increasing severity and hospitalization risks. Read More

FDA Approves Penpulimab-Kcqz for Indications in Nonkeratinizing Nasopharyngeal Carcinoma

Source: Pharmacy Times articles The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine. Read More

For Colon Cancer That No Longer Responds to Treatment, A New Drug Combination Offers Hope

Source: Pharmacy Times articles Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care. Read More

Sacituzumab Govitecan-hziy Plus Pembrolizumab Improves PFS in Patients With Metastatic Triple-Negative Breast Cancer

Source: Pharmacy Times articles The combination yielded superior progression-free (PFS) survival compared with standard of care. Read More

From Workflow Integration to Patient Outcomes: The Expanding Role of PQIs

Source: Pharmacy Times articles Ginger Blackmon, PharmD, explains how NCODA’s Positive Quality Interventions (PQIs) help improve oncology care by guiding best practices, supporting teamwork, and streamlining workflows. Read More

Hormonal Contraceptive Initiation Associated With Increased Risk of Depression Postpartum in First-Time Mothers

Source: Pharmacy Times articles Because mothers are already at risk of depression postpartum, health care professionals must properly counsel mothers on hormonal contraceptives. Read More

Recent Publications

Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks...

Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review

Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT...

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background:...

Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis

Curr Probl Cancer. 2025 Apr 3;56:101202. doi: 10.1016/j.currproblcancer.2025.101202. Online ahead...

Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis

Cancer Rep (Hoboken). 2025 Apr;8(4):e70171. doi: 10.1002/cnr2.70171. ABSTRACT BACKGROUND: The...

Email

info@myeloma360.com